A Monte Carlo Simulation of Advanced HIV Disease

A. David Paltiel, Julie A. Scharfstein, George R. Seage, Elena Losina, Sue J. Goldie, Milton C. Weinstein, Donald E. Craven and Kenneth A. Freedberg

Medical Decision Making, 1998, vol. 18, issue 2_suppl, S93-S105

Abstract: Background. Disagreement exists among decision makers regarding the allocation of limited HIV patient care resources and, specifically, the comparative value of prevent ing opportunistic infections in late-stage disease. Methods. A Monte Carlo simulation framework was used to evaluate a state-transition model of the natural history of HIV illness in patients with CD4 counts below 300/mm 3 and to project the costs and con sequences of alternative strategies for preventing AIDS-related complications. The au thors describe the model and demonstrate how it may be employed to assess the cost-effectiveness of oral ganciclovir for prevention of cytomegalovirus (CMV) infec tion. Results. Ganciclovir prophylaxis confers an estimated additional 0.7 quality-ad justed month of life at a net cost of $10,700, implying an incremental cost-effective ness ratio of roughly $173,000 per quality-adjusted life year gained. Sensitivity analysis reveals that this baseline result is stable over a wide range of input data estimates, including quality of life and drug efficacy, but it is sensitive to CMV incidence and drug price assumptions. Conclusions. The Monte Carlo simulation framework offers decision makers a powerful and flexible tool for evaluating choices in the realm of chronic disease patient care. The authors have used it to assess HIV-related treatment options and continue to refine it to reflect advances in defining the pathogenesis and treatment of AIDS. Compared with alternative interventions, CMV prophylaxis does not appear to be a cost-effective use of scarce HIV clinical care funds. However, targeted pre vention in patients identified to be at higher risk for CMV-related disease may warrant consideration. Key words: Monte Carlo simulation; AIDS; HIV infection; cytomegalo virus infection; cost-effectiveness analysis. (Med Decis Making 1998;18suppl:S93- S105)

Date: 1998
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (9)

Downloads: (external link)
https://journals.sagepub.com/doi/10.1177/0272989X98018002S11 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:sae:medema:v:18:y:1998:i:2_suppl:p:s93-s105

DOI: 10.1177/0272989X98018002S11

Access Statistics for this article

More articles in Medical Decision Making
Bibliographic data for series maintained by SAGE Publications ().